| 產品名稱 | F98npEGFRvIII |
|---|---|
| 商品貨號 | B210185 |
| Organism | Rattus norvegicus, rat |
| Tissue | brain |
| Cell Type | Glioblastoma |
| Product Format | frozen |
| Morphology | glial |
| Culture Properties | adherent |
| Biosafety Level | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | undifferentiated malignant glioma |
| Age | fetus, 20 days gestation |
| Applications | This cell line has been used for in vivo studies of molecular targeting of EGFRvIII in syngeneic Fischer rats. Ref   Yang W, et al. Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Taregeting Studies with Monoclonal Antibody L8A4. Clin. Cancer Res. 11(1): 341-350, 2005. PubMed: 15671565 |
| Storage Conditions | liquid nitrogen vapor phase |
| Derivation | Epidermal Growth Factor Receptor (EGFR)-expressing F98 glioma cells (F98EGFR) were produced by transfecting F98 (ATCC CRL-2397) with an expression vector containing human EGFRvIII cDNA. |
| Receptor Expression | Epidermal Growth Factor Receptor vIII (EGFRvIII), expressed (verified at ATCC) |
| Tumorigenic | YES |
| Effects | tumorigenic in syngeneic Fischer rats |
| Comments | EGFRvIII is a truncated extracellular mutant of the EGF receptor commonly found in glioblastomas that confers enhanced tumorigenic behavior. The receptors are very weakly phosphorylated. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002.
To make the complete growth medium, add the following components to the base medium:
|
| Subculturing | Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Note: If cells are cultured continuously, add 0.6 mg/mL G-418 to the complete growth medium for a passage about once a month.
Subcultivation ratio: A subcultivation ratio of 1:6 to 1:10 is recommended. Medium renewal: Every 2 to 3 days. |
| Cryopreservation | Freeze medium: complete growth medium, 95%; DMSO, 5% liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| Population Doubling Time | about 17 hours |
| Name of Depositor | RF Barth |
| Year of Origin | April 2001 |
| References | Yang W, et al. Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Taregeting Studies with Monoclonal Antibody L8A4. Clin. Cancer Res. 11(1): 341-350, 2005. PubMed: 15671565 Yang W, et al. Convection enhanced delivery of boronated epidermal growth factor for molecular targeting of EGFR positive gliomas. Cancer Res. 62: 6552-6558, 2002. PubMed: 12438250 Barth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929 Wu G, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1): 52-59, 2006. PubMed: 16432162. Wu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838 Yang W, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14(3): 883-891, 2008. PubMed: 18245552 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
